Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 3/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.82 |
| ▸ | GAA | P10253 | 2/20 | 0.82 |
| ▸ | TP53 | P04637 | 1/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | PPARG | P37231 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9754552 | 0.91 | MEN1 (0.84) | PRMT1ALDH1A1GAATP53MEN1 | |
| Acetonitrile SCHEMBL27336000 | 0.91 | PRMT1 (0.71) | PRMT1ALDH1A1GAATP53MEN1 | |
| SCHEMBL1287271 | 0.90 | ALDH1A1 (1.00) | PRMT1ALDH1A1GAATP53MEN1 | |
| SCHEMBL9131036 | 0.89 | TBXA2R (0.82) | PRMT1ALDH1A1GAATP53MEN1 | |
| SCHEMBL17372561 | 0.88 | ALDH1A1 (0.79) | PRMT1ALDH1A1GAATP53MEN1 | |
| SCHEMBL412302 | 0.88 | ALDH1A1 (0.79) | PRMT1ALDH1A1GAAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3517769 | 0.86 | ALDH1A1 (0.77) | PRMT1ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL9485046 | 0.85 | MEN1 (0.75) | PRMT1ALDH1A1GAATP53MEN1 | |
| SCHEMBL9754483 | 0.85 | MEN1 (0.75) | PRMT1ALDH1A1GAATP53MEN1 | |
| SCHEMBL9329691 | 0.85 | MEN1 (0.75) | PRMT1ALDH1A1GAATP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809584-B2 | N-substituted-N-phenylethylsulfonamides for the identification of biological and pharmacological activity | INSTITUT UNIV. DE CIENCIA I TECNOLOGIA, S.A. (ES) | 2014-08-19 | — | — | US | disclosed |
| US-20120149909-A1 | N-SUBSTITUTED-N-PHENYLETHYLSULFONAMIDES FOR THE IDENTIFICATION OF BIOLOGICAL AND PHARMACOLOGICAL ACTIVITY | AMIRA THERAPEUTICS, S.L. (ES) | 2012-06-14 | — | — | US | disclosed |
| US-20120122920-A1 | LIBRARIES OF N-SUBSTITUTED-N-PHENYLETHYLSULFONAMIDES FOR DRUG DISCOVERY | INSTITUT UNIV. DE CIENCIA I TECNOLOGIA, S. A. (ES) | 2012-05-17 | — | — | US | disclosed |
| US-20120122710-A1 | LIBRARIES OF N-SUBSTITUTED-N-PHENYLETHYLSULFONAMIDES FOR THE IDENTIFICATION OF BIOLOGICAL AND PHARMACOLOGICAL ACTIVITY | INSTITUT UNIV. DE CIENCIA I TECNOLOGIA, S. A. (ES) | 2012-05-17 | — | — | US | disclosed |
| WO-2012047926-A2 | SULFONAMIDE-CONTAINING COMPOUNDS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| US-5681961-A | TREATMENT AND/OR PREVENTION OF THROMBOEMBOLIC DISORDERS, ARTERIOSCLEROSIS, METASTASIS. ISCHEMIA, ASTHMA, ALLERGIES | DR. KARL THOMAE GMBH (DE) | 1997-10-28 | — | — | US | disclosed |
| EP-0397044-B1 | Arylsulfonamides, medicines containing these compounds and process for their preparation | THOMAE GMBH DR K (DE) | 1995-12-27 | — | — | EP | disclosed |
| CN-1111453-A | Aryl sulfonamide derivatives and pharmaceutical compositions containing the same | NIPPON KOKAN KK (JP) | 1995-11-08 | — | — | CN | disclosed |
| US-5426119-A | Thromboxane antagonists | DR. KARL THOMAE GMBH (DE) | 1995-06-20 | — | — | US | disclosed |
| US-5294626-A | Thromboxane synthesis inhibitors and anticoagulants | DR. KARL THOMAS GMBH (DE) | 1994-03-15 | — | — | US | disclosed |
| WO-1991013868-A1 | PHENYLTHIOALKYLCARBOXYLIC ACID DERIVATIVES, METHOD FOR PREPARING THEM AND DRUGS CONTAINING THESE COMPOUNDS | BOEHRINGER MANNHEIM GMBH (DE) | 1991-09-19 | — | — | WO | disclosed |
| EP-0397044-A2 | Arylsulfonamides, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122920-A1 | LIBRARIES OF N-SUBSTITUTED-N-PHENYLETHYLSULFONAMIDES FOR DRUG DISCOVERY | TST, PNMT, PTPRS | PRMT1 541/4885ALDH1A1 1565/4885GAA 1983/4885 |
| US-20120149909-A1 | N-SUBSTITUTED-N-PHENYLETHYLSULFONAMIDES FOR THE IDENTIFICATION OF BIOLOGICAL AND PHARMACOLOGICAL ACTIVITY | NAT1, TST, PNMT | PRMT1 622/4885ALDH1A1 2578/4885GAA 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.